Albendazole OxideCAS# 54029-12-8 |
- Leuprolide Acetate
Catalog No.:BCC1701
CAS No.:74381-53-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 54029-12-8 | SDF | Download SDF |
PubChem ID | 83969 | Appearance | Powder |
Formula | C12H15N3O3S | M.Wt | 281.33 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | methyl N-(6-propylsulfinyl-1H-benzimidazol-2-yl)carbamate | ||
SMILES | CCCS(=O)C1=CC2=C(C=C1)N=C(N2)NC(=O)OC | ||
Standard InChIKey | VXTGHWHFYNYFFV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C12H15N3O3S/c1-3-6-19(17)8-4-5-9-10(7-8)14-11(13-9)15-12(16)18-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Albendazole Oxide Dilution Calculator
Albendazole Oxide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.5545 mL | 17.7727 mL | 35.5454 mL | 71.0909 mL | 88.8636 mL |
5 mM | 0.7109 mL | 3.5545 mL | 7.1091 mL | 14.2182 mL | 17.7727 mL |
10 mM | 0.3555 mL | 1.7773 mL | 3.5545 mL | 7.1091 mL | 8.8864 mL |
50 mM | 0.0711 mL | 0.3555 mL | 0.7109 mL | 1.4218 mL | 1.7773 mL |
100 mM | 0.0355 mL | 0.1777 mL | 0.3555 mL | 0.7109 mL | 0.8886 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Albendazole Oxide
- Amifampridine
Catalog No.:BCC5185
CAS No.:54-96-6
- Pentylenetetrazole
Catalog No.:BCC7453
CAS No.:54-95-5
- Isoniazid
Catalog No.:BCC9003
CAS No.:54-85-3
- Cinanserin hydrochloride
Catalog No.:BCC6653
CAS No.:54-84-2
- Pilocarpine HCl
Catalog No.:BCC4702
CAS No.:54-71-7
- Idoxuridine
Catalog No.:BCC4666
CAS No.:54-42-2
- Metyrapone
Catalog No.:BCC7632
CAS No.:54-36-4
- Furosemide
Catalog No.:BCC3782
CAS No.:54-31-9
- Sodium salicylate
Catalog No.:BCC4846
CAS No.:54-21-7
- 5-Hydroxyindole-3-Acetic Acid
Catalog No.:BCC8285
CAS No.:54-16-0
- Tryptophan
Catalog No.:BCN2615
CAS No.:54-12-6
- L-Nicotine
Catalog No.:BCN6269
CAS No.:54-11-5
- Etonogestrel
Catalog No.:BCC5230
CAS No.:54048-10-1
- Tofacitinib (CP-690550) Citrate
Catalog No.:BCC2189
CAS No.:540737-29-9
- Palosuran
Catalog No.:BCC4311
CAS No.:540769-28-6
- Isoastilbin
Catalog No.:BCN5719
CAS No.:54081-48-0
- 2-(1-Hydroxy-1-methylethyl)-4-methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Catalog No.:BCN1422
CAS No.:54087-32-0
- L-Carnitine inner salt
Catalog No.:BCN1229
CAS No.:541-15-1
- Decamethonium Bromide
Catalog No.:BCC4568
CAS No.:541-22-0
- Isovaleramide
Catalog No.:BCC4668
CAS No.:541-46-8
- Muscone
Catalog No.:BCN6275
CAS No.:541-91-3
- 15-Hydroxydehydroabietic acid
Catalog No.:BCN5720
CAS No.:54113-95-0
- 9-Benzylcarbazole-3-carboxaldehyde
Catalog No.:BCC8800
CAS No.:54117-37-2
- Apoptosis Inhibitor
Catalog No.:BCC1143
CAS No.:54135-60-3
Effect of aminoguanidine and albendazole on inducible nitric oxide synthase (iNOS) activity in T. spiralis-infected mice muscles.[Pubmed:16201316]
Folia Histochem Cytobiol. 2005;43(3):157-9.
The aim of this study was to provide evidence for the expression of iNOS in the cells of inflammatory infiltrates around larvae in skeletal muscles of T. spiralis infected mice. The BALB/c mice (n = 8) divided into subgroups, received either aminoguanidine (AMG)--a specific iNOS inhibitor or albendazole (ALB)--an antiparasitic drug of choice in trichinellosis treatment. Control animals (n = 2 in each subgroup) were either uninfected and treated or uninfected and untreated. Frozen sections of hind leg muscles from mice sacrificed at various time intervals after infection were cut and subjected to immunohistochemistry, using monoclonal anti-iNOS antibody. The ALB-treated mice revealed stronger iNOS staining in the infiltrating cells around larvae than the infected and untreated animals. On the contrary, in the AMG-treated animals, the infiltrating cells did not show any specific iNOS reaction. These data confirm the specificity of iNOS staining in the cellular infiltrates around T. spiralis larvae and shed some light on the role of nitric oxide during ALB treatment in experimental trichinellosis.
Examination of commercially available copper oxide wire particles in combination with albendazole for control of gastrointestinal nematodes in lambs.[Pubmed:26790729]
Vet Parasitol. 2016 Jan 15;215:1-4.
Control of gastrointestinal nematodes (GIN) remains a critical issue due to the prevalence of anthelmintic resistance. The objective of the experiment was to determine the efficacy of copper oxide wire particles (COWP) from three commercial sources and a combination of COWP and albendazole to control GIN and/or Haemonchus contortus in lambs. Naturally infected Katahdin lambs in early June 2014 and 2015 were randomly assigned to receive no COWP (CON; n=9 and 12) or 2g COWP in a gel capsule as Copasure((R)) (COP; n=4 and 17; Animax Ltd.), copper oxide-wire form (AUS; n=7 in 2014 only; Pharmplex), Ultracruz (ULT; n=8 and 15; Santa Cruz Animal Health), no COWP and albendazole (CON+alb; n=10 in 2015 only; 15mg/kg BW; Valbazen((R)); Zoetis Animal Health), or COWP+alb (n=7 and 11; in 2014, lambs were administered alb on day 3). Lambs grazed grass pastures as a group and were supplemented with 227g/lamb daily of a commercial grain mix (15% crude protein) and the same amount of alfalfa pellets. Feces were collected on days 0 (day of COWP treatment), 7, and 14 for determination of fecal egg counts (FEC). Pooled (2014) or pooled treatment group feces were cultured on days 0, 7, and 14 (2015 only) to determine GIN genera. Data were analyzed using repeated measures in a mixed model, and FEC were log transformed. The predominant GIN on day 0 was H. contortus (87%) in 2014, and there was a mixed population in 2015. The mean FEC was reduced by day 7 in AUS and ULT lambs (treatmentxday, P=0.001), and all of the COWP products were similar. By day 14, the AUS FEC were lower than the CON and COP groups. When examining the combination of COWP and synthetic anthelmintic, the FEC of COWP+alb were reduced to nearly 0eggs/g (back-transformed) and lower than the other groups (treatmentxday, P=0.001). The percentage of H. contortus in cultured feces was reduced to a greater extent in the COWP than CON or CON+alb groups of lambs. In a mixed GIN population, the COWP products appeared to be similar in efficacy and using a combination of COWP+alb increased the efficacy not only against H. contortus, but all GIN genera present, offering options in the face of resistance to benzimidazoles.
Copper(II) oxide nanoparticles augment antifilarial activity of Albendazole: In vitro synergistic apoptotic impact against filarial parasite Setaria cervi.[Pubmed:26827921]
Int J Pharm. 2016 Mar 30;501(1-2):49-64.
Mass treatment of lymphatic filariasis with Albendazole (ABZ), a therapeutic benzimidazole, is fraught with serious limitations such as possible drug resistance and poor macrofilaricidal activity. Therefore, we need to develop new ABZ-based formulations to improve its antifilarial effectiveness. CuO nanoparticles were used as an adjuvant with ABZ to form ABZ-CuO nanocomposite, which was characterized by UV-vis spectroscopy, FT-IR, AFM and SEM. Antifilarial activity of nanocomposite was evaluated using relative motility assay and dye exclusion test in dark and under UV light. ROS generation, antioxidant levels, lipid peroxidation and DNA fragmentation in nanocomposite treated parasites were estimated. Biophysical techniques were employed to ascertain the mode of binding of nanocomposite to parasitic DNA. Nanocomposite increases parasite mortality as compared to ABZ in dark, and its antifilarial effect was increased further under UV light. Elevated ROS production and decline of parasitic-GST and GSH levels were observed in nanocomposite treated worms in dark, and these effects were pronounced further under UV light. Nanocomposite leads to higher DNA fragmentation as compared to ABZ alone. Further, we found that nanocomposite binds parasitic DNA in an intercalative manner where it generates ROS to induce DNA damage. Thus, oxidative stress production due to ROS generation and consequent DNA fragmentation leads to apoptosis in worms. This is the first report supporting CuO nanoparticles as a potential adjuvant with ABZ against filariasis along with enhanced antifilarial activity of nanocomposite under UV light. These findings, thus, indicate that development of ABZ-loaded nanoparticle compounds may serve as promising leads for filariasis treatment.